ClinicalTrials.gg
CompletedNCT00953680Updated Feb 9, 2022Results posted

Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)

A Phase 1 interventional study of losartan potassium (+) hydrochlorothiazide (HCTZ) and losartan potassium in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Organon and Co · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
37th of 65
77 · median 100
Started
2004
with 4 others
Phase 1
9 of 65
1 open now
Registered
25th of 65
by date
Lead sponsor
7 of 65
Organon and Co

Among the 65 studies testing losartan in Hypertension, this one is the 37th largest by enrollment, is one of 5 that started in 2004, is one of 9 in phase 1, and was the 25th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

This study will evaluate the bioequivalence of the losartan/hydrochlorothiazide (HCTZ) combination tablet and coadministration of losartan and hydrochlorothiazide.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is a healthy male or female between the ages of 18 and 45 years of age
  • Subject does not smoke

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of any illness that might pose additional risk to participation or confound the results of the study
  • Subject has a history of or C or significant drug allergies
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    losartan /HCTZ combination tablet

    single dose losartan 100 mg/HCTZ 12.5 mg combination tablet

    Drug: losartan potassium (+) hydrochlorothiazide (HCTZ)

  • Active comparator
    losartan tablet + HCTZ capsule

    Single dose losartan 100 mg tablet + HCTZ 12.5 mg capsule

    Drug: losartan potassium · Drug: hydrochlorothiazide (HCTZ)

Interventions

  • Druglosartan potassium (+) hydrochlorothiazide (HCTZ)

    Drug page: Hydrochlorothiazide

    Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.

  • Single dose losartan 100 mg tablet in one of two treatment periods.

    Also known as: COZAAR™

  • Single dose HCTZ 12.5 mg capsule in one of two treatment periods.

    Also known as: MICROZIDE™

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC(0 to Infinity)) of Losartan

    Time frame: 0 to 36 Hours Post Dose

  2. Peak Plasma Concentration (Cmax) for Losartan

    Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing.

    Time frame: 36 Hours Post Dose

  3. Area Under the Curve (AUC(0 to Infinity)) of HCTZ

    Plasma Area Under the Curve, a measure of drug exposure following dosing

    Time frame: 0 to 30 Hours Post Dose

  4. Peak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ

    Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing

    Time frame: 30 Hours Post Dose

07

Results

Posted Jul 16, 2010
Limitations and caveats
PK analyses included complete data from 75 subjects. 3 losartan/E-3174 concentrations from 3 different subjects were excluded from analyses due to gross deviations; 75 minutes-Treatment B, 75 minutes-Treatment A, \& 15 minutes-Treatment A.

Participant flow

Period 1
Participant flow — Period 1
MilestoneLosartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ CapsuleLosartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet
Started3839
Completed3838
Not completed01
Withdrew: Withdrawal by subject01
Period 2
Participant flow — Period 2
MilestoneLosartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ CapsuleLosartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet
Started3838
Completed3838
Not completed00

Outcome measures

PrimaryArea Under the Curve (AUC(0 to Infinity)) of Losartan
Time frame:
0 to 36 Hours Post Dose
Reported as:
Least squares mean · ng*hr/mL
Area Under the Curve (AUC(0 to Infinity)) of Losartan
ng*hr/mLLosartan-HCTZ Combination TabletLosartan Tablet + HCTZ Capsule
Area Under the Curve (AUC(0 to Infinity)) of Losartan1018.1 ± 382.51024.9 ± 354.6
Statistical analysis
  • Losartan-HCTZ Combination Tablet vs Losartan Tablet + HCTZ Capsule · Least-squares mean ratio: 0.993 · 90% CI 0.950 to 1.039
PrimaryPeak Plasma Concentration (Cmax) for Losartan

Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing.

Time frame:
36 Hours Post Dose
Reported as:
Least squares mean · ng/mL
Peak Plasma Concentration (Cmax) for Losartan
ng/mLLosartan-HCTZ Combination TabletLosartan Tablet + HCTZ Capsule
Peak Plasma Concentration (Cmax) for Losartan532.7 ± 334.9637.9 ± 425.3
Statistical analysis
  • Losartan-HCTZ Combination Tablet vs Losartan Tablet + HCTZ Capsule · Least-squares mean ratio: 0.835 · 90% CI 0.749 to 0.931
PrimaryArea Under the Curve (AUC(0 to Infinity)) of HCTZ

Plasma Area Under the Curve, a measure of drug exposure following dosing

Time frame:
0 to 30 Hours Post Dose
Reported as:
Least squares mean · ng*hr/mL
Area Under the Curve (AUC(0 to Infinity)) of HCTZ
ng*hr/mLLosartan-HCTZ Combination TabletLosartan Tablet + HCTZ Capsule
Area Under the Curve (AUC(0 to Infinity)) of HCTZ462.08 ± 144.72499.90 ± 133.46
Statistical analysis
  • Losartan-HCTZ Combination Tablet vs Losartan Tablet + HCTZ Capsule · Least-squares mean ratio: 0.924 · 90% CI 0.825 to 1.035
PrimaryPeak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ

Peak Plasma Concentration (Cmax), or maximal concentration of drug following dosing

Time frame:
30 Hours Post Dose
Reported as:
Least squares mean · ng/mL
Peak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ
ng/mLLosartan-HCTZ Combination TabletLosartan Tablet + HCTZ Capsule
Peak Plasma Concentration (Cmax) of HCTZ Following Single Dose Administration of Losartan/HCTZ or Losartan and HCTZ76.15 ± 39.5581.76 ± 31.05
Statistical analysis
  • Losartan-HCTZ Combination Tablet vs Losartan Tablet + HCTZ Capsule · Least-squares mean ratio: 0.931 · 90% CI 0.836 to 1.037

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Losartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ Capsule—0/38 (0%)12/76 (15.8%)
Losartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet—0/39 (0%)10/77 (13%)
Most frequent other events
Most frequent other events
EventLosartan-HCTZ Combination Tablet/Losartan Tablet +HCTZ CapsuleLosartan Tablet +HCTZ Capsule/Losartan-HCTZ Combination Tablet
HeadacheNervous system disorders8/766/77
DizzinessNervous system disorders5/763/77
VomitingGastrointestinal disorders1/761/77
Alanine Aminotransferase IncreasedInvestigations1/760/77
Aspartate Aminotransferase IncreasedInvestigations1/760/77
NauseaGastrointestinal disorders0/761/77

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean33.87 (18 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female46
Male31
Height
Height(Centimeters)All Participants
Mean166.81 (152 to 191)
Weight
Weight(kilograms)All Participants
Mean73.01 (50 to 99.1)
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of May 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 6 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2009
First posted
Aug 6, 2009
Start
Apr 2004
Primary completionActual
May 2004
CompletionActual
Jul 2004
Results first posted
Jul 16, 2010
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00953680
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 6, 2009
Start date
Apr 2004
Primary completion
May 2004
Completion
Jul 2004
Results posted
Jul 16, 2010
Last update
Feb 9, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion